The FDA has approved two new weight loss medications within a two-week period: Foundayo (orforglipron) on April 2, 2026, and Zepbound (tirzepatide) on March 22, 2026. Both drugs are indicated for chronic weight management in adults with obesity or overweight conditions alongside diet and exercise. This rapid approval timeline represents an unusually fast pace for metabolic health drug approvals, suggesting strong clinical evidence and urgent medical need.
